SCHEMBL29598517

SCHEMBL29598517

Nc1ncnc2c1ncn2[C@@H]1O[C@H](CCC(=O)c2cccc(C(=O)O)c2)[C@@H](O)[C@H]1O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNMT Q14749 3/20 0.71
NNMT P40261 6/20 0.62
DOT1L Q8TEK3 2/20 0.58
DPP4 P27487 1/20 0.58
MEN1 O00255 1/20 0.58
SLC28A1 O00337 1/20 0.58
MAP3K7 O43318 1/20 0.58
SLC28A2 O43868 1/20 0.58
GAPDH P04406 1/20 0.58
ADORA3 P0DMS8 1/20 0.58
MAPK1 P28482 1/20 0.58
ADORA2A P29274 1/20 0.58
ADORA2B P29275 1/20 0.58
ADORA1 P30542 1/20 0.58
STAT6 P42226 1/20 0.58
PI4KA P42356 1/20 0.58
KMT2A Q03164 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
PI4K2B Q8TCG2 1/20 0.58
SLC29A1 Q99808 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29598730 0.85 TYMP (0.57) GNMTNNMT
SCHEMBL19302866 0.84 GNMT (0.60) GNMT
SCHEMBL19302805 0.84
Adenosine SCHEMBL11656001 0.83 ADORA3 (0.78) GNMTDOT1LDPP4MEN1SLC28A1
SCHEMBL19302871 0.83 GNMT (0.59) GNMTNNMT
SCHEMBL11519694 0.80 NNMT (0.76) GNMTNNMTDOT1LDPP4MEN1
SCHEMBL14696727 0.79 NNMT (0.78) GNMTNNMTDOT1LDPP4MEN1
SCHEMBL16486489 0.79 EHMT1 (0.75) NNMTDOT1LDPP4MEN1SLC28A1
SCHEMBL10766543 0.79 EHMT1 (0.75) NNMTDOT1LDPP4MEN1SLC28A1
SCHEMBL5972642 0.78 DOT1L (0.76) NNMTDOT1LDPP4MEN1SLC28A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197344-A1 COMPOUNDS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS VICTORIA LINK LIMITED (NZ) 2025-06-19 US disclosed
US-12258304-B2 Compounds and methods for treatment of bacterial infections ALBERT EINSTEIN COLLEGE OF MEDICINE (US) 2025-03-25 US disclosed
US-11948662-B2 Metabolite, annotation, and gene integration system and method THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-04-02 US disclosed
US-20220234995-A1 COMPOUNDS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS ALBERT EINSTEIN COLLEGE OF MEDICINE (US) 2022-07-28 US disclosed
US-20220127311-A1 CELL FACTORIES FOR IMPROVED PRODUCTION OF COMPOUNDS AND PROTEINS DEPENDENT ON IRON SULFUR CLUSTERS BIOSYNTIA APS (DK) 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197344-A1 COMPOUNDS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS FNTB, PGLS, FUT6 GNMT 468/4885NNMT 469/4885DOT1L 4139/4885
US-12258304-B2 Compounds and methods for treatment of bacterial infections FNTB, PGLS, FUT6 GNMT 468/4885NNMT 469/4885DOT1L 4139/4885
US-20220234995-A1 COMPOUNDS AND METHODS FOR TREATMENT OF BACTERIAL INFECTIONS FNTB, PGLS, FUT6 GNMT 468/4885NNMT 469/4885DOT1L 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.